% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • jacosa jacosa Mar 6, 2013 12:10 PM Flag

    Serious comments on Cowen presentation

    Usual request not to go slanging each other in this topic.

    Biggest news by far is that a trial is being planned for ruxo in first-line treatment of pancreatic CA. You can blind all you want; it's pretty obvious how patients are doing overall in a study of a group expected to waste away and die in 2 months. Yeah, you follow up your failures as well as your successes, but not so quickly. Too soon to set off the fireworks, but you can order them.

    Idea floated of allowing the label reference to clinical trials showing a survival benefit in MF is very attractive. No way will FDA allow a flat claim of live extension, but this might actually pass. Sales force still has to point to the reference, but it would multiply credibility.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
86.565-1.925(-2.18%)9:37 AMEDT